Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

ent of elderly patients with high risk diffuse large B-cell lymphoma (DLBCL) relapse after treatment with R-CHOP. Treatment options for patients who are ineligible for autologous stem cell transplant are limited. In this analysis, of the 63 patients enrolled on the study, 39 patients had been treated with Zevalin. The median age is 75 years (range 62-86); Karnofsky performance status was <80 percent in 59 percent of patients with a median performance status of 70 percent; prognostic score was high-intermediate/high in 53 percent and 47 percent of patients, respectively. Moderate or high impact comorbidity is present in 86 percent. In the intent-to-treat population, progression-free (PFS) and overall survival (OS) were 59 percent and 65 percent, respectively, at 22 months. In the 39 patients who received Zevalin, PFS and OS were 78 percent and 82 percent, respectively, at 26 months. Responses improved in 11 patients who received Zevalin, with eight patients improving from an unconfirmed (CRu) to a confirmed complete response (CR) and three patients improving from a partial response (PR) to a CR/CRu. The side effects reported included blood count suppression: 26 percent and 36 percent grade 3/4 neutropenia, 15 percent grade 3 anemia, and 36 percent and 31 percent grade 3/4 thrombocytopenia. Six patients had delayed blood count recovery for more than 12 weeks. One patient developed myelodysplasia and two patients died after Zevalin was given, one from a suspected brain hemorrhage and one from congestive heart failure.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

R
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Novation, the leading health ... awarded several new IT value-added reseller (VAR) national ... organizations with IT goods and services at lower ... as well as value-added services such as initiative ... New Novation agreements were awarded to CDW ...
(Date:1/15/2014)... -- BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ... Ltd (NYSE: TEVA ) and its subsidiaries ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ... Symphony® CGM System as a non-invasive, wireless continuous ... F. Doman , Executive Chairman and Interim CEO ... Financial Capital Markets, Tenth Annual Equity Conference. ... presentation to prospective corporate partners and investors at ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... ... a new market research report is available in its ... A Worldwide Market Review , http://www.reportlinker.com/p0164338/Respiratory-Care-Equipment--Supplies---A-Worldwide-Market-Review.html ... driving the respiratory care equipment & supplies market. Novel ...
... , NEW YORK, Dec. 8 ... is available in its catalogue: , Training Manikins ... Training manikins, capable of replicating real-life trauma conditions, are ... are in use across various institutions including hospitals, military, ...
Cached Medicine Technology:Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 2Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 3Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 4Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 5Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 6Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 7Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 8Reportlinker Adds Respiratory Care Equipment & Supplies - A Worldwide Market Review 9Reportlinker Adds Training Manikins - Global Trends 2Reportlinker Adds Training Manikins - Global Trends 3Reportlinker Adds Training Manikins - Global Trends 4Reportlinker Adds Training Manikins - Global Trends 5
(Date:4/14/2014)... chemotherapy over the past decade, but targeting drugs to ... a major challenge. , Nanotechnology has unlocked new ... nanocarriers, or capsules, that can transport cargoes of small-molecule ... catch? These carriers are tiny, and it matters just ... nanometers to 100 nanometers, and the drugs can end ...
(Date:4/14/2014)... reached a medical milestone April 3, performing the ... way to access the heart. , Henry Ford ... performing the unique procedure called transcaval valve replacement, ... blood vessels. , Northern Michigan resident Viola Waller, ... July 3, 2013 when traditional valve replacement was ...
(Date:4/14/2014)... one of the scientific marvels of the 20th century, ... won against bacterial infections. But scientists at the University ... to restoring its combat effectiveness, even against so-called "superbugs." ... of the penicillin family of drugs since their first ... the staph infection, brought about by the bacterium ...
(Date:4/14/2014)... in their radiation treatment decisions leaves cancer patients ... even relieve psychological distress around the experience, researchers ... the University of Pennsylvania report in the ... of 305 patients undergoing radiation treatment, Neha ... department in Radiation Oncology at Penn Medicine, and ...
(Date:4/14/2014)... Popular web information on colorectal cancer is too difficult ... the appropriate risks to and concerns of patients, a ... In a review of a dozen popular websites, most ... screening were written beyond the recommended sixth-grade reading level, ... risks, as well as the barriers to and benefits ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3
... -- The prestigious BBVA Foundation Frontiers of Knowledge Award ... J. Lefkowitz, M.D., James B. Duke Professor of Medicine ... investigator at Duke University Medical Center. This is only ... Dr. Lefkowitz,s research has affected millions of cardiac and ...
... U.S. Department of Energy,s National Nuclear Security Administration (NNSA) ... of radioisotopes, which are used to help millions of ... cancer, thyroid and heart disease. Earlier this week, ... develop a U.S. supply of Molybdenum-99 (Mo-99). Babcock & ...
... a new generation of products aimed at making cleaning ... in the current issue of Chemical & Engineering News ... Editor Michael McCoy points out in the cover story ... occurring despite a rocky economy in 2009, which led ...
... scent of urine could catch disease quickly , WEDNESDAY, Jan. 27 ... that can detect lung cancer simply on the basis of a ... is so far based solely on work with mice, but follow-up ... in the early diagnosis of lung cancer in humans. , "But ...
... ... regenerates dormant hair follicles to produce new growth is not being recommended by the researchers ... effective hair loss treatment options are already available. , ... (PRWeb UK) January 28, 2010 -- Researchers and hair restoration surgeons ...
... , WASHINGTON , Jan. 27 ... (SCAI) launched "WINHeart -- Score a WIN for Women," ... the diagnosis, treatment and survival of women with cardiovascular ... of interventional cardiologists within SCAI, today released a new ...
Cached Medicine News:Health News:Renowned Duke researcher wins Frontiers of Knowledge Award 2Health News:SNM applauds US Department of Energy's move to develop domestic radioisotope supply 2Health News:New Test Might 'Smell' Early Stage Lung Cancer 2Health News:New Test Might 'Smell' Early Stage Lung Cancer 3Health News:Hair Cloning Not Yet Recommended by Researchers Who Developed the Technique 2Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 2Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 3Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 4Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 5
Universal Hub with Varying Blade Edge Diameters For Mounting the Blade to the Handle; Stainless Steel....
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel....
Blunt Tapered Tip in stainless steel....
... meet the high-quality and ... practices. The optional Profile ... accessory features a unique ... increases the accuracy of ...
Medicine Products: